MedPath

Major Oral Rinse

0.12% Major Unit Dose Cups

Approved
Approval ID

b48e69dc-0913-423f-e053-2a95a90a53df

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 23, 2022

Manufacturers
FDA

Major Pharmaceuticals

DUNS: 191427277

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

0.12% Chlorhexidine Gluconate

PRODUCT DETAILS

NDC Product Code0904-7035
Application NumberANDA077789
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateNovember 23, 2022
Generic Name0.12% Chlorhexidine Gluconate

INGREDIENTS (6)

GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
SACCHARIN SODIUMInactive
Code: SB8ZUX40TY
Classification: IACT
CHLORHEXIDINE GLUCONATEActive
Quantity: 1.2 mg in 1 mL
Code: MOR84MUD8E
Classification: ACTIB
WATERInactive
Code: 059QF0KO0R
Classification: IACT
FD&C BLUE NO. 1Inactive
Code: H3R47K3TBD
Classification: IACT
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 11/20/2020

NDC 0904-7035-88

Chlorhexidine Gluconate Oral Rinse USP, 0.12%

0.12% / 15 mL

Delivers 15 mL

See insert

For Institutional Use Only • Rx Only

MAJOR® PHARMACEUTICALS

Livonia, MI 48152

1999MJRLIDLBL

MJR LID

1999MJRUDINST

MJR INST1MJR INST2MJR INST3MJR INST4

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 11/20/2020

INDICATION

Chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 11/20/2020

CONTRAINDICATIONS

Chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 11/20/2020

ADVERSE REACTIONS

The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS. Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate oral rinse.

The following oral mucosal side effects were reported during placebo- controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occured at a frequency of less than 1%.

Among post marketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse are stomatits, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.

Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse.

Threre have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

LOINC: 34083-6Updated: 11/20/2020

Carcinogenisis, Mutagenisis, and Impairment of Fertility

In a drinking water study in rats, carcinogenic effects were not observed at doses up to 38mg/kg/day. Mutagenic effects were not observed in two mammalian in vivo mutagenisis studies with chlorhexidine gluconate. The highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenisis test were 1000mg/kg/day and 250mg/kg/day, respectively. No evidence of impaired fertility was observed in rats at doses up to 100mg/kg/day.

DESCRIPTION SECTION

LOINC: 34089-3Updated: 11/20/2020

DESCRIPTION

0.12% chlorhexidine gluconate (CHG) is an oral rinse
containing (1, 11-hexamethylene bis [5-(p-chlorophenyl) biguanide]
di-D-gluconate) in a base containing water, 11.6% alcohol, glycerin,
PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue
No.1. Chlorhexidine gluconate product is a near neutral solution (pH range
5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid.
Its chemical structure is:

MJR chem structure

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 11/20/2020

CLINICAL PHARMACOLOGY

Chlorhexidine gluconate oral rinse provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general reduction of counts of certain assayed becteria, both aerobic and anaerobic, ranging from 54-97% through six months use. Use of chlorhexidine gluconate oral rinse in a six month clinical study did not result in any significant changes in bacterial resistance, overgrowth of potentially opportunistic organisms or other adverse changes in the oral microbial ecosystem. Three months after chlorhexidine gluconate oral rinse use was discontinued, the number of bacteria in plaque had returned to baseline levels and resistance of plaque bacteria to chlorhexidine was equal to that as baseline.

PHARMACOKINETICS SECTION

LOINC: 43682-4Updated: 11/20/2020

Pharmacokinetics

Pharmacokinetic studies with chlorhexidine gluconate oral rinse indicate approximately 30% of the active ingredient, chlorhexidine gluconate, is retained in the oral cavity following rinsing. This retained drug is slowly released in the oral fluids. Studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. The mean plasma level of chlorhexidine gluconate reached a peak of 0.206 mcg/g in humans 30 minutes after they ingested a 300-mg dose of the drug. Detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. Excretion of chlorhexidine gluconate occured primarily through the feces (~90%). Less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

WARNINGS SECTION

LOINC: 34071-1Updated: 11/20/2020

WARNINGS

The effect of chlorhexidine gluconate oral rinse on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS.

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 11/20/2020

PRECAUTIONS

General:

1. For patients having coexisting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with chlorhexidine gluconate oral rinse should not be used as a major indicator or underlying periodontitis

2. Chlorhexidine gluconate oral rinse can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. Not all patients will experience a visually significant increase in toothstaining. In clinical testing, 56% of chlorhexidine gluconate oral rinse users exhibited a measurable increase in facial anterior stain, compared to 35% of control users after six months; 15% of chlorhexidine gluconate oral rinse users developed what was judged to be heavy stain, compared to 1% of control users after six months. Stain will be more pronounced in patients who have heavier accumulations of unremoved plaque. Stain resulting from use of chlorhexidine gluconate oral rinse does not adversely affect health health of the gingivae or other oral tissues. Stain can be removed from most tooth surfaces by conventional professional prophylactic techniques. Additional time may be required to complete the prophylaxis, patients should be excluded from chlorhexidine gluconate oral rinse treatment if permanent discoloration is unacceptable. Stain in these areas may be difficuly to remove by dental prophylaxis and on rare occasions may necessitate replacement of these restorations.

3. Some patients may experience an alteration in taste perception while undergoing treatment with chlorhexidine gluconate oral rinse. Rare instances of permanent taste alteration following chlorhexidine gluconate oral rinse use have been reported via post-marketing product surveillance.

PREGNANCY SECTION

LOINC: 42228-7Updated: 11/20/2020

Pregnancy: Teratogenic Effects

Reproduction studies have been performed in rats and rabbits at chlorhexidine gluconate doses up to 300mg/kg/day and 40mg/kg/day respectively, and have not revealed evidence of harm to fetus. However, adequate and well-controlled studies in pregnant women have not been done. Because animal reproduciton studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

NURSING MOTHERS SECTION

LOINC: 34080-2Updated: 11/20/2020

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when chlorhexidine gluconate oral rinse is administered to nursing women.

In parturition and lactation studies with rats, no evidence of impaired parturition or of toxic effects to suckling pups was observed when chlorhexidine gluconate was administered to dams at doses that were over 100 times greater than that which would result from a person's ingesting 30 ml of chlorhexidine gluconate oral rinse per day.

PEDIATRIC USE SECTION

LOINC: 34081-0Updated: 11/20/2020

Pediatric Use

Clinical effectiveness and safey of chlorhexidine gluconate oral rinse have not been established in children under the age of 18.

OVERDOSAGE SECTION

LOINC: 34088-5Updated: 11/20/2020

OVERDOSAGE

Ingestion of 1 or 2 ounces of chlorhexidine gluconate oral rinse by a small child (~10kg body weight) might result in gastric distress, including nausea, or signs of alcohol intoxication. Medical attention should be sought if more than 4 ounces of chlorhexidine gluconate oral rinse is ingested by a small child or if signs of alcohol intoxication develop.

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 11/20/2020

DOSAGE AND ADMINISTRATION

Chlorhexidine gluconate oral rinse therapy should be initiated directly following a dental prophylaxis. Patients using chlorhexidine gluconate oral rinse should be reevaluated and given a thorough prophylaxis at intervals no linger than six months.

Recommended use is twice daily rinsing for 30 seconds, morning and evening after tooth brushing. Usual dosage os 15 ml of undiluted chlorhexidine gluconate oral rinse. Patients should be instructed to not rinse with water, or other mouthwashes, brush teeth, or eat immediately after using chlorhexidine gluconate oral rinse. Chlorhexidine gluconate oral rinse is not intended for ingestion and should be expectorated after rinsing.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 11/20/2020

HOW SUPPLIED

Chlorhexidine gluconate oral rinse is supplied as a blue liquid in 0.5-ounce (15 ml) (NDC 0904-7035-88) white plastic unit dose cups, 0.5-ounce (15 ml) (NDC 0904-7035-87) white plastic unit dose cups (40 pack) and 0.5-ounce (15 ml) (NDC 0904-7035-80) white plastic unit dose cups (100 pack).

Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [See USP controlled Room Temperature].

OTHER SAFETY INFORMATION

LOINC: 60561-8Updated: 11/20/2020

STORE at 20ºC to 25ºC (68ºF to 77ºF), 30ºC (59ºF to 86ºF) [See USP controlled Room Temperature].

Rx Only.

KEEP OUT OF REACH OF CHILDREN.

Revised: September 2020

Distributed by:

MAJOR® PHARMACEUTICALS

17177 N Laurel Park Dr., Suite 233

Livonia, MI 48152

© Copyright 2025. All Rights Reserved by MedPath
Major Oral Rinse - FDA Approval | MedPath